BROOMFIELD, Colo. — August 4, 2026 — Leads & Copy — Aclarion, Inc., a commercial-stage healthcare technology company utilizing biomarkers and artificial intelligence (AI) algorithms to assist physicians in pinpointing the source of chronic low back pain, announced that its Nociscan platform is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent. This marks the first site in Indiana to offer the technology, extending Aclarion’s provider network into a new state.
Goodman Campbell Brain & Spine is recognized nationally for its role in neurosurgery training and clinical research, consistently ranking among the nation’s best. The physician specialists at the center are known for their dedication to advanced treatment approaches and data-driven outcome measures aimed at enhancing patient health.
“Every patient we see with chronic low back pain deserves a clear answer about where their pain is coming from before we talk about treatment. For years, MRI alone hasn’t been able to give us that answer; it shows us the anatomy, but not which disc is actually the source of pain,” said Dr. Eric A. Potts, Neurosurgeon and Spine Specialist at Goodman Campbell Brain & Spine. “Bringing Nociscan into our practice reflects the standard we hold ourselves to at Goodman Campbell: if there’s a tool that gives our patients and our team better information, we want to be among the first to offer it.”
Nociscan employs Magnetic Resonance Spectroscopy (MRS) to extract and quantify chemical biomarkers associated with disc pain. The platform provides objective, non-invasive insights that enable physicians to differentiate between painful and non-painful discs in the lumbar spine, a capability that MRI lacks. Nociscan offers critical information regarding the location of a patient’s low back pain, and studies show a 97% surgical success rate when all Nociscan-positive discs are treated.
“Goodman Campbell’s reputation for clinical excellence and its role in training the next generation of neurosurgeons make them an important addition to the Nociscan network,” stated Brent Ness, CEO of Aclarion. “The addition of each new site reflects the growing momentum behind Nociscan adoption as we work to bring this technology within reach of more patients living with chronic low back pain.”
Chronic low back pain is a significant global healthcare issue, affecting approximately 266 million people worldwide who suffer from degenerative spine disease and low back pain. Aclarion is focused on expansion and increasing its network of provider sites across the country.
For more information on Nociscan or to find a Nociscan center, visit Aclarion’s website.
About Aclarion, Inc.
Aclarion is a healthcare technology company that utilizes Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is initially addressing the chronic low back pain market with Nociscan, an evidence-supported, SaaS platform designed to noninvasively help physicians distinguish between painful and non-painful discs in the lumbar spine. Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. Proprietary algorithms then indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, enabling physicians to optimize treatment strategies.
Source: Aclarion, Inc.
